File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.

TitleDeterminants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.
Authors
KeywordsCyclophosphamide
Ethnicity
Lupus nephritis
Mycophenolate mofetil
Survival
Issue Date2006
PublisherInternational Society on Hypertension in Blacks. The Journal's web site is located at http://www.ishib.org/ED_index.asp
Citation
Ethnicity & Disease., 2006, v. 16 n. 2 Suppl 2, p. S2-66-S2-69 How to Cite?
AbstractINTRODUCTION: Systemic lupus erythematosus is more prevalent among Asians, African Americans, and Hispanics than in Caucasians. Progress in its management over the past few decades has resulted in improved patient survival, although a considerable proportion of patients are still afflicted with long-term illnesses such as chronic renal failure secondary to lupus nephritis. METHODS AND RESULTS: This is a review of the factors that affect the survival of patients with systemic lupus erythematosus, including discussion of the measures that can further improve the clinical outcomes and prevent long-term complications. Recent advances in the treatment of severe lupus nephritis are emphasized, especially with regard to the minimization of treatment-related adverse events. CONCLUSIONS: While the prognosis of patients with severe lupus manifestations continues to improve, prevention of relapse remains a clinical challenge. Concomitant attention to health economics and sociopolitical issues is required to ensure that all patients can benefit from scientific progress in the understanding and treatment of severe lupus erythematosus.
Persistent Identifierhttp://hdl.handle.net/10722/162998
ISSN
2021 Impact Factor: 2.006
2020 SCImago Journal Rankings: 0.767

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:26:23Z-
dc.date.available2012-09-05T05:26:23Z-
dc.date.issued2006en_US
dc.identifier.citationEthnicity & Disease., 2006, v. 16 n. 2 Suppl 2, p. S2-66-S2-69en_US
dc.identifier.issn1049-510Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162998-
dc.description.abstractINTRODUCTION: Systemic lupus erythematosus is more prevalent among Asians, African Americans, and Hispanics than in Caucasians. Progress in its management over the past few decades has resulted in improved patient survival, although a considerable proportion of patients are still afflicted with long-term illnesses such as chronic renal failure secondary to lupus nephritis. METHODS AND RESULTS: This is a review of the factors that affect the survival of patients with systemic lupus erythematosus, including discussion of the measures that can further improve the clinical outcomes and prevent long-term complications. Recent advances in the treatment of severe lupus nephritis are emphasized, especially with regard to the minimization of treatment-related adverse events. CONCLUSIONS: While the prognosis of patients with severe lupus manifestations continues to improve, prevention of relapse remains a clinical challenge. Concomitant attention to health economics and sociopolitical issues is required to ensure that all patients can benefit from scientific progress in the understanding and treatment of severe lupus erythematosus.en_US
dc.languageengen_US
dc.publisherInternational Society on Hypertension in Blacks. The Journal's web site is located at http://www.ishib.org/ED_index.aspen_US
dc.relation.ispartofEthnicity & disease.en_US
dc.subjectCyclophosphamide-
dc.subjectEthnicity-
dc.subjectLupus nephritis-
dc.subjectMycophenolate mofetil-
dc.subjectSurvival-
dc.subject.meshAdrenal Cortex Hormones - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Administration & Dosageen_US
dc.subject.meshLupus Nephritis - Drug Therapy - Ethnology - Mortalityen_US
dc.subject.meshMycophenolic Acid - Administration & Dosage - Analogs & Derivativesen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshUnited States - Epidemiologyen_US
dc.titleDeterminants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.en_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid16774014en_US
dc.identifier.scopuseid_2-s2.0-34250781200en_US
dc.identifier.hkuros117902-
dc.identifier.volume16en_US
dc.identifier.issue2 Suppl 2en_US
dc.identifier.spageS2-66en_US
dc.identifier.epages2-69en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US
dc.customcontrol.immutablejt 130423-
dc.identifier.issnl1049-510X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats